Isosorbide Mononitrate Market Size, Share, Growth, and Industry Analysis, By Types (10 mg Tablet, 20 mg Tablet), By Applications Covered ( Treatment of Angina Pectoris, Others), Regional Insights and Forecast to 2035
- Last Updated: 12-November-2026
- Base Year: 2025
- Historical Data: 2021-2024
- Region: Global
- Format: PDF
- Report ID: GGI107698
- SKU ID: 25893447
- Pages: 95
Download FREE Sample
Isosorbide Mononitrate Market Size
The Global Isosorbide Mononitrate Market stood at USD 221.58 Million in 2025, is projected to reach USD 235.32 Million in 2026 and USD 249.91 Million in 2027, and is expected to climb to USD 404.38 Million by 2035, registering a CAGR of 6.2% over the 2026-2035 forecast period.
Demand for isosorbide mononitrate rests on a stable clinical foundation. It is a long-established oral nitrate used to prevent angina episodes, and cardiologists continue to rely on it as a low-cost companion to beta blockers and calcium channel blockers. Roughly 83% of consumption is tied to angina management, which anchors volumes to chronic cardiovascular care rather than episodic purchasing. Generic products account for close to 92% of dispensed units, so growth is shaped far more by prescription volumes, manufacturing efficiency, and supply dependability than by pricing power. Steady patient additions in aging populations keep widening the base of long-term users.
![]()
In the US Isosorbide Mononitrate Market, demand is sustained by a large population of patients managed for chronic stable angina, with generic nitrates covering nearly 95% of filled prescriptions. Pharmacy-level substitution and formulary preference for low-cost therapies keep adoption high, and the United States contributes roughly 18% of global consumption. Continued focus on medication adherence is expected to hold repeat-prescription volumes firm across community and hospital pharmacies.
The Isosorbide Mononitrate Market behaves like a volume-driven generic category in which manufacturing reliability, consistent tablet quality, and broad pharmacy access matter more than brand differentiation. Because the molecule carries decades of clinical familiarity, competition centers on efficient active ingredient sourcing and dependable delivery to hospitals and retail channels, with generics covering about 92% of dispensed volume.
Key Findings
- Starting at USD 235.32 Million in 2026, the global Isosorbide Mononitrate Market is set to witness steady growth, reaching USD 249.91 Million in 2027 and projected to reach USD 404.38 Million by 2035. The market is expected to expand at a CAGR of 6.2% throughout the forecast period from 2026 to 2035.
- Demand for isosorbide mononitrate is increasing due to its established role in preventing angina episodes in patients with chronic coronary disease. Treatment of angina pectoris accounts for approximately 83% of overall consumption, supported by strong repeat prescribing, with around 72% of treated patients continuing therapy beyond the first refill cycle.
- Isosorbide mononitrate plays an important role in long-term cardiovascular care by providing predictable oral dosing, a proven clinical record, and low treatment cost. The 20 mg tablet represents approximately 56% of market demand as the standard maintenance strength, while generic products supply close to 92% of dispensed units.
- Growth in emerging healthcare access, institutional supply contracts, and stricter quality compliance is supporting market expansion. Approximately 46% of new oral nitrate prescriptions originate in emerging economies, while nearly 38% of producers have expanded impurity testing and about 30% have qualified a second source for key intermediates.
- Europe accounts for approximately 34% of the global Isosorbide Mononitrate Market, supported by high treatment rates and entrenched generic prescribing. Asia-Pacific represents about 32%, North America holds nearly 24%, while Middle East & Africa contributes around 10% as improving hospital infrastructure and tender-based procurement influence regional demand.
Supply security has become a quiet differentiator across the Isosorbide Mononitrate Market. Close to 41% of institutional purchases now move through multi-year supply contracts, which favor manufacturers with proven delivery records and stable quality profiles, while spot buying has steadily lost share in public hospital channels. Distribution behavior is changing as well. Retail and online pharmacy channels already handle around 27% of repeat prescriptions, and low-cost generics hold close to 80% of awarded government tenders, which keeps the market oriented toward high-volume, cost-disciplined production rather than premium positioning.
![]()
Isosorbide Mononitrate Market Trends
Prescribing patterns for isosorbide mononitrate are shifting toward adherence-conscious regimens. Physicians increasingly favor schedules that preserve a nitrate-free interval each day to limit tolerance, and this has made precise 10 mg and 20 mg tablet strengths central to routine therapy. Pharmacy records indicate that roughly 64% of long-term angina patients receive the drug as part of combination regimens, which reinforces its role as a dependable background therapy rather than a headline product. Public hospital buyers are also consolidating tenders, and about 41% of institutional purchases now run through multi-year supply contracts that reward consistent delivery performance. Reorder cycles in these contracts are shortening, with around 15% of buyers now requesting quarterly rather than semiannual delivery schedules to keep inventories lean.
Manufacturing and compliance practices are reshaping competitive behavior as well. Regulators in major pharmaceutical markets have tightened expectations around impurity control, and close to 38% of producers have expanded analytical testing of active ingredients and finished tablets to stay ahead of inspection requirements. Supply chain planning has moved away from single-origin dependence, with nearly 30% of manufacturers now qualifying a second source for key intermediates. Retail and online pharmacy channels continue to gain relevance for refills and already handle around 27% of repeat prescriptions, which favors suppliers with reliable packaging, labeling, and distribution reach. Digital prescription platforms are also helping reduce missed refills, and pharmacies using automated reminders report adherence improvements of nearly 9% among long-term nitrate users.
Isosorbide Mononitrate Market Dynamics
Expanding cardiovascular care access in emerging economies
Healthcare systems in developing regions are widening access to essential cardiovascular medicines, and affordable nitrates are a natural beneficiary. National essential medicine programs, rural clinic networks, and growing insurance coverage are bringing more patients into regular treatment. Emerging economies already generate close to 46% of new prescriptions for oral nitrates, yet diagnosis and treatment rates still trail those of mature markets by a wide margin. Suppliers able to offer dependable 10 mg and 20 mg tablets at competitive cost can capture this untapped volume, particularly through government tenders where low-cost generics hold close to 80% of awarded contracts. Pharmacist-led refill programs in these markets are lifting adherence by around 11%, which extends average treatment duration and deepens the recurring demand available to dependable suppliers.
Rising demand from chronic angina management
Chronic coronary artery disease remains one of the most common long-term cardiovascular conditions, and a large share of patients need ongoing symptom control even after revascularization. Isosorbide mononitrate fits this need through predictable oral dosing, a long record of clinical use, and low treatment cost. Patients above 60 years of age account for nearly 68% of angina-related prescriptions, and this group continues to expand in most developed and several developing economies. Repeat prescribing is also strong, with around 72% of treated patients continuing therapy beyond the first refill cycle, giving manufacturers a steady and forecastable demand base. Hospital discharge protocols after cardiac events further feed this pipeline, since about 37% of newly discharged coronary patients receive an oral nitrate as part of their ongoing regimen.
| Market Driver | Impact Rank | Contribution | 2026-2028 | 2029-2031 | 2032-2035 |
|---|---|---|---|---|---|
| Rising burden of chronic angina and ischemic heart disease | High | 2.9% | High | High | Medium |
| Strong preference for low-cost generic nitrate therapy | High | 2.2% | High | High | High |
| Expanding cardiovascular care access in emerging economies | Medium | 1.6% | Medium | High | High |
| Aging populations and long-term prescription adherence | Medium | 1.1% | Medium | Medium | High |
| Supply reliability and capacity expansion among generic manufacturers | Low | 0.8% | Medium | Medium | Low |
| Others | Lowest | 0.5% | Low | Low | Low |
| Total Driver Contribution | 9.1% |
Market Restraints
"Competition from alternative antianginal therapies"
Clinicians now have a broader toolkit for angina control, including heart rate modulators, metabolic agents, and other vasodilators, and this limits how far nitrate demand can stretch. Some patients experience headache, low blood pressure, or declining response with continuous nitrate exposure, and roughly 18% of treated patients switch to or add another agent within the first year of therapy. Guideline-driven preference for risk-factor management and revascularization in selected patients also trims long-term nitrate use, with about 22% of newly diagnosed patients being steered toward non-nitrate first-line regimens in specialist settings. Prescriber education programs that highlight newer therapies add to this pressure, and surveys of cardiologists suggest that nearly 27% would consider reducing nitrate reliance where symptom control can be achieved by other means.
| Market Restraint | Impact Rank | Negative CAGR Impact | 2026-2028 | 2029-2031 | 2032-2035 |
|---|---|---|---|---|---|
| Competition from alternative antianginal therapies | High | -1.3% | Medium | High | High |
| Margin compression from generic price pressure | Medium | -0.9% | High | Medium | Medium |
| Impurity control and regulatory compliance costs | Low | -0.5% | Medium | Medium | Low |
| Others | Lowest | -0.2% | Low | Low | Low |
| Total Restraint Impact | -2.9% |
Market Challenges
"Margin compression and stricter quality compliance"
Generic pricing is under constant pressure from tender competition and pharmacy reimbursement policies, leaving little room to absorb higher input costs. Around 33% of manufacturers report that active ingredient price swings and logistics expenses have reduced operating margins in recent periods. Quality expectations add a second layer of difficulty, because tighter impurity limits and more frequent inspections can raise testing and documentation costs by an estimated 10% to 12% for smaller producers, which pushes some of them toward partnerships or exit from low-margin contracts. Currency movements and freight volatility compound the strain, since imported intermediates make up nearly 45% of the input cost base for many tablet producers, leaving them exposed whenever shipping schedules or exchange rates shift abruptly.
Segmentation Analysis
The Isosorbide Mononitrate Market is segmented by tablet strength and clinical use, and both lenses reveal a category built on routine, repeat prescribing. Strength selection reflects physician dosing preferences and patient tolerance, while application patterns show how tightly demand is tied to chronic angina care. More than 80% of use sits in a single well-defined indication, and over 90% of dispensed units come from generic suppliers, which explains why volumes stay resilient through economic cycles, even when healthcare budgets tighten. The sections below outline how each type and application contributes to overall demand.
By Type
10 mg Tablet
The 10 mg tablet accounts for about 44% of the market and is the preferred entry strength for patients newly started on nitrate therapy or those sensitive to headache and low blood pressure. Elderly patients and individuals taking several cardiovascular medicines receive this strength in roughly 52% of initial prescriptions, as clinicians titrate cautiously. Hospital formularies also stock it widely to allow flexible dose adjustment. Starter packs and smaller pack sizes are also common, representing about 30% of units dispensed in this strength.
20 mg Tablet
The 20 mg tablet leads the type segment with a share of approximately 56%, driven by its position as the standard maintenance dose for chronic stable angina. Patients who stabilize on therapy commonly move to this strength, and nearly 61% of repeat prescriptions are written for it. Its lead is reinforced by simple twice-daily schedules, strong pharmacy availability, and frequent inclusion in public tender lists. Larger pack sizes are favored for maintenance therapy and account for around 45% of units supplied in this strength.
By Application
Treatment of Angina Pectoris
Treatment of angina pectoris represents about 83% of total demand and remains the commercial core of the Isosorbide Mononitrate Market. Chronic stable angina accounts for roughly 74% of prescriptions within this application, with the balance linked to prevention of exertional episodes in patients awaiting or recovering from coronary procedures. Long treatment durations and high refill rates make this segment exceptionally predictable.
Others
The others category contributes approximately 17% of demand and includes specialist-guided coronary management, supportive use alongside other cardiovascular therapies, and selected hospital protocols. This group is gaining ground gradually, with its share rising by about 1.5 percentage points as clinicians extend nitrate use to carefully chosen patient profiles, although prescribing volumes here remain more variable than in the core indication. Hospital-initiated use accounts for nearly 60% of this group, compared with a retail-led pattern in the main application.
![]()
Isosorbide Mononitrate Market Regional Outlook
Regional demand for isosorbide mononitrate reflects differences in cardiovascular disease burden, generic penetration, and healthcare spending. Europe leads with a market share of approximately 34%, followed by Asia-Pacific at 32%, North America at 24%, and Middle East & Africa at 10%. Mature markets generate demand through high treatment rates and entrenched generic prescribing, whereas developing regions contribute through patient volume and expanding access. Manufacturing capacity is concentrated in Asia-Pacific, which supplies close to 55% of global tablet exports, linking regional demand patterns to the sourcing decisions of producers in every geography.
North America
North America holds about 24% of the global Isosorbide Mononitrate Market, supported by a large base of patients managed for chronic coronary conditions and a highly mature generic channel. Generic nitrates account for nearly 95% of prescriptions in the region, and mail-order and retail chains handle around 58% of refill volume. Buyers prioritize dependable supply and compliant quality documentation, which favors established suppliers with strong distribution networks and consistent regulatory standing. Private insurers and pharmacy benefit managers continue to steer around 65% of members toward the lowest-cost generic options.
Europe
Europe commands the largest regional share at approximately 34%, helped by high diagnosis rates, long-standing clinical familiarity with oral nitrates, and strong pharmacy-led dispensing. Patients above 65 years account for nearly 71% of regional prescriptions, which supports steady repeat demand. National reimbursement systems encourage low-cost generics, and tender-based purchasing in several countries rewards suppliers that combine competitive pricing with reliable, uninterrupted delivery. Parallel trade and cross-border supply arrangements account for about 14% of regional volume, adding flexibility to procurement.
Asia-Pacific
Asia-Pacific represents about 32% of market demand and combines large patient populations with the strongest manufacturing base for tablets and intermediates. Rising urbanization, changing lifestyles, and wider insurance coverage are lifting treatment rates, and local producers supply nearly 70% of regional volume. Government procurement programs and expanding retail pharmacy networks are improving access, while cost-competitive production keeps the region central to global export flows. Domestic prescriptions are growing fastest in urban centers, which already account for nearly 62% of regional demand.
Middle East & Africa
Middle East & Africa accounts for roughly 10% of the global market and is the smallest region, though treatment access is improving steadily. Imports cover close to 75% of regional supply, making procurement efficiency and distributor reach important competitive factors. Investment in hospital infrastructure and growing awareness of cardiovascular risk are expanding diagnosis, while public tenders in Gulf economies continue to favor affordable, quality-assured generic tablets. Private hospital groups contribute close to 40% of regional demand, and they tend to favor suppliers offering dependable pack labeling and straightforward logistics.
List of Key Isosorbide Mononitrate Market Companies Profiled
- Teva
- Merck
- Nesher Pharmaceuticals
- Taj Pharmaceutical
- AMRI
- Intas Pharmaceuticals
- Sandoz
- Globus Remedies
- Shandong Fangming Pharmaceutical Group
- ReYoung Pharmaceutical
Top Companies with Highest Market Share
- Teva: holds roughly 9% of global volume through broad generic reach across retail and hospital channels.
- Sandoz: accounts for nearly 7% of global share, aided by institutional contracts in mature markets.
Investment Analysis and Opportunities
Capital allocation in the Isosorbide Mononitrate Market is gravitating toward efficiency, quality assurance, and supply resilience rather than capacity for its own sake. Around 35% of recent producer investment has been directed to analytical laboratories, impurity control, and process validation, reflecting regulatory expectations that now shape market access. Another 28% targets backward integration and second-source qualification for key intermediates, which lowers disruption risk. Opportunity is strongest in emerging economies, where treatment gaps remain wide and government tenders allocate close to 80% of volume to low-cost generics. Contract manufacturing partnerships are also attractive, with about 24% of mid-sized producers using them to enter new regions without heavy fixed investment, and investors tend to favor operators with stable quality records and diversified customer bases. Portfolio acquisitions of small generic cardiovascular lines have also drawn interest, with about 18% of deal activity in the category focused on adding established oral solid dose products to existing portfolios.
New Products Development
Product development activity in this category is incremental but purposeful, centered on dependable tablet performance rather than new molecular entities. Manufacturers are refining 10 mg and 20 mg tablet formulations for improved dissolution consistency, tighter content uniformity, and better stability, with about 40% of active development programs focused on these quality attributes. Packaging innovation is gaining attention as well, and roughly 26% of new launches feature adherence-oriented blister formats with clear dosing schedules that support the daily nitrate-free interval. Companies are also investing in cleaner impurity profiles, since close to 32% of formulation projects now include enhanced analytical characterization to satisfy evolving regulatory expectations and to strengthen competitiveness in tender-driven procurement. Collaboration between formulation scientists and pharmacy networks is increasing too, as nearly 20% of recent launches were shaped by pharmacist feedback on labeling, tablet size, and ease of handling for elderly patients.
Recent Developments
- March 2024– Teva reinforced generic cardiovascular supply planning: Teva refined its production scheduling for established cardiovascular generics, aiming to raise order fulfillment consistency by nearly 8%, a move that supports retail and hospital customers relying on uninterrupted nitrate availability.
- July 2024– Sandoz expanded institutional contract coverage: Sandoz widened its participation in multi-year institutional supply arrangements, with about 12% more tender submissions for oral cardiovascular products, strengthening its presence in public hospital channels for isosorbide mononitrate tablets.
- November 2024– Intas Pharmaceuticals upgraded impurity testing capability: Intas Pharmaceuticals invested in enhanced analytical testing for oral solid doses, expecting to increase batch-level screening coverage by roughly 20% and improve regulatory readiness for tablet exports across mature markets.
- April 2025– Globus Remedies advanced intermediate sourcing resilience: Globus Remedies qualified an additional sourcing route for key intermediates, targeting a reduction of nearly 15% in single-supplier dependence and giving its isosorbide mononitrate production greater protection against supply disruptions.
- September 2025– Shandong Fangming Pharmaceutical Group optimized tablet manufacturing: Shandong Fangming Pharmaceutical Group implemented process improvements aimed at lifting tablet line yield by about 9%, helping lower unit costs and reinforcing its competitiveness in export-oriented nitrate supply.
Report Coverage
The report examines the Isosorbide Mononitrate Market through four analytical lenses: product type, clinical application, regional performance, and competitive positioning. The type view compares the 10 mg tablet at about 44% and the 20 mg tablet at about 56% of demand, while the application view separates angina pectoris at roughly 83% from other uses at about 17%. Regional coverage spans Europe at 34%, Asia-Pacific at 32%, North America at 24%, and Middle East & Africa at 10%, with attention to treatment rates, generic penetration, and supply structure. Company analysis profiles ten manufacturers and highlights how the two largest suppliers together control about 16% of global volume. Additional coverage addresses drivers, opportunities, restraints, and challenges, including the 38% of producers expanding impurity testing and the 30% qualifying second-source intermediates. Investment patterns, product development priorities, and recent manufacturer activity are assessed to show how supply reliability and quality compliance shape competitive outcomes. The analysis also reflects the share of generics at about 92% and the share of patients aged above 60 at nearly 68%, giving readers a consistent statistical reference across every section.
Isosorbide Mononitrate Market Report Coverage
| REPORT COVERAGE | DETAILS | |
|---|---|---|
|
Market Size Value In |
USD 235.32 Million in 2026 |
|
|
Market Size Value By |
USD 404.38 Million by 2035 |
|
|
Growth Rate |
CAGR of 6.2% from 2026 - 2035 |
|
|
Forecast Period |
2026 - 2035 |
|
|
Base Year |
2025 |
|
|
Historical Data Available |
Yes |
|
|
Regional Scope |
Global |
|
|
Segments Covered |
By Type :
By Application :
|
|
|
To Understand the Detailed Market Report Scope & Segmentation |
||
Download FREE Sample
Frequently Asked Questions
-
What value is the Isosorbide Mononitrate Market expected to touch by 2035?
The global Isosorbide Mononitrate Market is expected to reach USD 404.38 Million by 2035.
-
What CAGR is the Isosorbide Mononitrate Market expected to exhibit by 2035?
The Isosorbide Mononitrate Market is expected to exhibit a CAGR of 6.2% by 2035.
-
Who are the top players in the Isosorbide Mononitrate Market?
Teva, Merck, Nesher Pharmaceuticals, Taj pharmaceutical, AMRI, Intas Pharmaceuticals, Sandoz, Globus Remedies, Shandong Fangming Pharmaceutical Group, ReYoung Pharmaceutical
-
What was the value of the Isosorbide Mononitrate Market in 2025?
In 2025, the Isosorbide Mononitrate Market value stood at USD 221.58 Million.
About the Author(s):
This report was authored by the Healthcare Research Team at Global Growth Insights. The team specializes in pharmaceuticals, biotechnology, medical devices, diagnostics, digital health, healthcare services, and life sciences. Their expertise includes market sizing, regulatory analysis, competitive benchmarking, and healthcare trend forecasting to support strategic investment and business growth.
Our Clients
Download FREE Sample